William Barton / Shutterstock.com
29 January 2025NewsAmericasMuireann Bolger

GSK seeks damages hike in ‘skinny label’ case

Complex legal battle concerns ‘skinny label’ strategy used by generic drug makers, prompting a $235 million award | Pharma giant looks for enhanced damages due to ‘wilful infringement’, while opponent wants another trial.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
23 May 2023   Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.
article
16 May 2023   The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.